International Journal of Clinical Pharmacy

, Volume 34, Issue 5, pp 690–692 | Cite as

Overdose of pegfilgrastim: case report

  • Gisela RiuEmail author
  • Anna Estefanell
  • Meritxell Nomdedeu
  • Natàlia Creus
Case Report


Background Pegfilgrastim is a G-CSF that can be administered in a single dose 24 h after each cycle of chemotherapy. Case 59 years-old man with a stage III-B peripheral T lymphoma with CD4 expression. Dose-dense chemotherapy was started with CHOP-14 combined with pegfilgrastim as primary prophylaxis. An error in the dispensing system meant that the patient received pegfilgrastim for 4 consecutive days. He remained under observation in hospital. During the 3 days after the last dose of pegfilgrastim, the patient remained stable, with no remarkable symptoms or associated laboratory abnormalities, and was discharged. Conclusion The case we describe and the available literature lead us to suggest close monitoring as the main measure to be adopted when treating a patient for pegfilgrastim overdose.


Overdose Pegfilgrastim 


Conflicts of interest

The authors have no conflict of interest to declare.


  1. 1.
    Aapro M, Crawford J, Kamioner D. Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? Support Care Cancer. 2010;18:529–41.PubMedCrossRefGoogle Scholar
  2. 2.
    Neulasta® (pegfilgrastim) Summary of Product Characteristics (Spanish). Accessed Aug 27, 2010. Available from:
  3. 3.
    Dufour C, Cappelli B, Calvillo M, Fioredda F, Tonelli R. Similar favorable outcome of pegfilgrastim overdose in patients with different age and underlying disease. Haematologica. 2010;95:684–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Kaidar-Person O, Moskovitz M, Charas T, Alsharbati W, Haim N. Pegfilgrastim overdose: case report and review of the literature. Med Oncol. 2011;28(Suppl 1):697–8. Epub 2010 Nov 24.CrossRefGoogle Scholar
  5. 5.
    Donadieu J, Beupain B, Rety-Jacob F, Nove-Josserand R. Respiratory distress and sudden death of a patient with GSDIb chronic neutropenia: possible role of pegfilgrastim. Haematologica. 2009;94:1175–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Wolff AC, Jones RJ, Davidson NE, Jeter SC, Stearns V. Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support. J Clin Oncol. 2006;24:2392–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Gisela Riu
    • 1
    Email author
  • Anna Estefanell
    • 1
  • Meritxell Nomdedeu
    • 2
  • Natàlia Creus
    • 1
  1. 1.Pharmacy Service, Hospital Clínic de BarcelonaBarcelonaSpain
  2. 2.Hematology Service, Hospital Clínic de BarcelonaBarcelonaSpain

Personalised recommendations